Following interim results earlier this week, we’re taking the opportunity to update numbers to account for a variety of variables including currency, market backdrop/peer group and investment phasing. We think R&D costs – primarily associated with the ground-breaking US development programme for Pollinex Quattro Grass – will likely dig deeper particularly in FY17E, but increased investment in commercial infrastructure will see accelerated top line growth. Given the marke

10 Mar 2016
Panmure Morning Note 10-3-2016

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Panmure Morning Note 10-3-2016
Allergy Therapeutics plc (AGY:LON) | 7.6 0 (-4.7%) | Mkt Cap: 363.4m
- Published:
10 Mar 2016 -
Author:
Dr Mike Mitchell -
Pages:
3 -
Following interim results earlier this week, we’re taking the opportunity to update numbers to account for a variety of variables including currency, market backdrop/peer group and investment phasing. We think R&D costs – primarily associated with the ground-breaking US development programme for Pollinex Quattro Grass – will likely dig deeper particularly in FY17E, but increased investment in commercial infrastructure will see accelerated top line growth. Given the marke